In summary, the expression level of TIM-3 is closely related to Ann-Arbor stage, which may be expected to be a new indicator to evaluate the aggressiveness of DLBCL.PD-1 was correlated with the expression of LAG-3, and both the high expression of LAG-3 and LAG-3/PD-1 predicted the poor prognosis of DLBCL.Therefore, LAG-3 may be a new target for immunotherapy, and it can also be combined with PD-1 inhibitors to improve the drug resistance of current DLBCL patients, thus extending the survival of patients. Here, LAG3 is linked to diffuse large B-cell lymphoma.